Chase Sun Pharma Named in "Top 100 Comprehensive Strength in Drug R&D i

Xiongan, China – July 4, 2024: The 2024 International Pharmaceutical Service Industry Innovation Development Conference and the 9th China Pharmaceutical R&D and Innovation Summit (PDI) commenced today at the Xiongan Exhibition Center. In a highlight of the event, the "Top 100 Comprehensive Strength in Drug R&D in China 2024" list was officially unveiled, with Chase Sun Pharma earning a prestigious spot. This recognition underscores the company's significant contributions to pharmaceutical research and development, as well as its commitment to innovation.

The ranking, organized by Yaoshi Net, the China Pharmaceutical R&D Summit Committee, and China Pharmaceuticals, focused on pharmaceutical companies' innovation capabilities. It evaluated various R&D-related metrics from 2023, including drug approval statuses, R&D investment, clinical trial completions, and patent portfolios. The aim of the ranking is to promote the pharmaceutical innovation ecosystem and accelerate the high-quality development of China's innovative drug industry.

As a leading enterprise in the health industry with a focus on traditional Chinese medicine, Chase Sun Pharma considers scientific research and innovation as key drivers of its long-term growth and industry progress. The company boasts multi-level, diverse scientific and technical platforms that facilitate the transformation of technological achievements into productive forces. Additionally, Chase Sun Pharma collaborates closely with academic institutions for talent exchange and integration, advancing industry-academia-research collaboration to build high-level talent cultivation and innovation bases.

Chase Sun Pharma's sustained investment in research and innovation has yielded substantial results. The company's finished drug segment includes over ten drugs in various stages of research and market launch. Its traditional Chinese medicine formula granules utilize "intelligent digital" technology to ensure equivalence to decoctions, enhancing the user experience of Chinese medicine. In the medical device sector, Chase Sun Pharma integrates AI and big data, developing several core technologies to introduce a range of portable, smart health monitoring products, thereby expanding its international market influence.

These achievements reflect Chase Sun Pharma's dedication to scientific and technological innovation, and its proactive approach to high-quality development and industrial structure optimization.